Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 46.9%

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 5,200 shares, a decline of 46.9% from the November 15th total of 9,800 shares. Based on an average daily volume of 45,100 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on Avalo Therapeutics in a research note on Thursday, October 24th. They set a "neutral" rating for the company.

Institutional Trading of Avalo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. acquired a new position in Avalo Therapeutics during the third quarter valued at $9,186,000. Affinity Asset Advisors LLC grew its stake in Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company's stock valued at $561,000 after acquiring an additional 35,000 shares in the last quarter. Logos Global Management LP purchased a new stake in shares of Avalo Therapeutics in the second quarter worth approximately $6,722,000. Finally, Ikarian Capital LLC boosted its holdings in shares of Avalo Therapeutics by 1,673.0% during the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company's stock worth $9,218,000 after purchasing an additional 915,629 shares during the period. Institutional investors and hedge funds own 87.06% of the company's stock.

Avalo Therapeutics Stock Down 3.0 %

Shares of Avalo Therapeutics stock traded down $0.28 on Thursday, reaching $9.11. 55,453 shares of the company were exchanged, compared to its average volume of 203,961. Avalo Therapeutics has a fifty-two week low of $3.95 and a fifty-two week high of $34.46. The stock has a fifty day moving average price of $11.18 and a 200-day moving average price of $10.85.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.